CliffBio
small molecule

HERNEXEOS

ZONGERTINIB

Loss of exclusivityJuly 2041latest FDA-listed patent expiry
CompanyBoehringer Ingelheim →See this company's full patent-cliff portfolio

Drug detail

Brand nameHERNEXEOS
Active ingredientZONGERTINIB
Strength60MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

Listed patents

PatentExpiresType
11608343July 2041substance, product
12171739November 2026substance, product

Regulatory exclusivity

CodeExpires
NCEAugust 2030

More from Boehringer Ingelheim

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.